Metabolic · In-Market · Updated August 2026
In no other category is Medicare negotiation this central. It is not an exposure at the margin here; it is the main pricing event, and it arrives in sequence.
The treatment pathway has been reoriented around complications rather than glycaemic control alone. A large share of patients carry chronic kidney disease, and the condition remains a leading cause of kidney failure, blindness and amputation. That has pulled prescribing toward agents with demonstrated organ protection, and it means the commercially relevant segments are defined by comorbidity rather than by diagnosis alone. A substantial diagnosed population sits alongside a large undiagnosed one and a far larger prediabetic pool.
Negotiation is resetting the price structure class by class, across successive negotiation years rather than in a single event. As maximum fair prices take effect, the older oral classes reprice downward and the gap that justified holding newer agents behind a step narrows. A formulary position argued on relative cost in one year may not hold on the same arithmetic two years later, which makes the negotiation calendar a planning input rather than a background fact.
Within the newer class the contest runs on two tracks at once: share of new starts, which has been moving toward the more recent entrant, and formulary tier, which is responding to cardiovascular outcomes labelling. Reading either in isolation misstates the market.
AXLRx Type 2 diabetes reports size the complication-defined segments, read the class contest on both tracks, and model what each negotiated price does to step-edit economics. Each report is a sample output of the AXLRx commercial consulting engine, and the same analysis can be commissioned for your asset and market.
US diabetes prevalence is 38.4 million adults, or 11.6%, of whom 8.7 million are undiagnosed, and 90 to 95% of cases are Type 2; a further 97.6 million adults have prediabetes. Diagnosis follows the ADA A1c, fasting plasma glucose and oral glucose tolerance thresholds. What now drives the pathway is complication burden rather than glycaemic control alone: chronic kidney disease affects roughly one in three, and diabetes remains a leading cause of kidney failure, blindness and amputation. That has pulled prescribing toward agents with demonstrated organ protection.
More than any other. IPAY 2026 maximum fair prices, effective 1 January 2026, reset Januvia to $113, Jardiance to $197 and Farxiga to $178. IPAY 2027, effective a year later, cut semaglutide across Ozempic, Rybelsus and Wegovy by 71% to $274 a month and added Janumet and Tradjenta. Type 2 diabetes is not a category with negotiation exposure at the margin; negotiation is the central pricing event, and it is sequential rather than one-off.
They erode the economic case for the step edits that protected the older classes. Step therapy through SGLT2 inhibitors and DPP-4 agents was justified by the price gap between those classes and the GLP-1s. As maximum fair prices take effect, that anchor resets and the gap narrows, which weakens the rationale for holding a GLP-1 behind a step. The practical consequence is that a formulary position argued on relative cost in 2025 may not hold on the same arithmetic in 2027.
Tirzepatide holds about 41% of new GLP-1 starts, and semaglutide's SELECT cardiovascular outcomes label is driving formulary priority at Part D plans. The competition is running on two tracks at once: share of new starts, which is moving toward the newer agent, and formulary tier, which is responding to the outcomes label. An assessment of either in isolation will read the market wrongly.
A patient-flow and sizing read that separates diagnosed from undiagnosed and resolves the complication-defined segments driving prescribing; competitive intelligence on the GLP-1 class contest and the outcomes labels behind it; and a payer analysis of the sequential IRA negotiation schedule and what each maximum fair price does to step-edit economics and formulary tier. Each is scoped to your asset.